CIRAi007-A

Cell Line

Provider

External Databases

General Information

• Okita K et al. A more efficient method to generate integration-free human iPS cells. Nature methods. 2011 May;8(5):409-12.
• Kajiwara M et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2012 Jul 31;109(31):12538-43.
• Kondo T et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell stem cell. 2013 Apr 4;12(4):487-96.
• Koyanagi-Aoi M et al. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2013 Dec 17;110(51):20569-74.
• Yamashita A et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature. 2014 Sep 25;513(7519):507-11.
• Toyoda T et al. Cell aggregation optimizes the differentiation of human ESCs and iPSCs into pancreatic bud-like progenitor cells. Stem cell research. 2015 Mar;14(2):185-97.
• Ichiyanagi N et al. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem cell reports. 2016 Apr 12;6(4):496-510.
• Nishizawa M et al. Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell stem cell. 2016 Sep 1;19(3):341-54.
• Fujimori K et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nature medicine. 2018 Oct;24(10):1579-1589.

General